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Abstract
OBJECTIVES: Preclinical in vivo studies using omental tissue as a biomaterial for myocardial regeneration are promising and have not
previously been collated. We aimed to evaluate the effects of the omentum as a support for bioengineered tissue therapy for cardiac re-
generation in vivo.
METHODS: A systematic scoping review was performed. Only English-language studies that used bioengineered cardio-regenerative
tissue, omentum and ischaemic cardiomyopathy in vivo models were included.
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RESULTS: We initially screened 1926 studies of which 17 were included in the final qualitative analysis. Among these, 11 were methodologic-
ally comparable and 6 were non-comparable. The use of the omentum improved the engraftment of bioengineered tissue by improving cell re-
tention and reducing infarct size. Vascularization was also improved by the induction of angiogenesis in the transplanted tissue. Omentum-
supported bioengineered grafts were associated with enhanced host reverse remodelling and improved haemodynamic measurements.
CONCLUSIONS: The omentum is a promising support for myocardial regenerative bioengineering in vivo. Future studies would benefit
from more homogenous methodologies and reporting of outcomes to allow for direct comparison.
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ABBREVIATIONS
LVEF Left ventricular ejection fraction
MI Myocardial infarction
INTRODUCTION
Ischaemic heart disease remains the leading global cause of mortal-
ity and is rising in prevalence with population growth, ageing effects
and shifting epidemiological trends [1, 2]. For end-stage heart failure
patients, transplantation and mechanical circulatory assistance devi-
ces are 2 of the limited options to restore a better quality of life [3].
Donor shortage and the limited regenerative potential of myocar-
dium have led to the recent development of numerous cell-based
therapies for cardiac tissue engineering [2, 4–10].
The omentum has been used as a support for cardiac bio-
engineering to overcome some of the challenges in myocardial
regeneration, such as poor vascularization and engraftment of
bioengineered tissue [2, 11–14]. It has regenerative properties
that have been exploited in surgical techniques, such as omental
transposition, where the omentum is extended or wrapped
around another tissue to promote healing, including the heart in
cardio-omentopexy [15]. It is thought that these regenerative
capabilities are linked to the presence of angiogenic factors,
including vascular endothelial growth factor, basic fibroblast
growth factor and an abundance of progenitor cells [16]. Its
abundance of collagens, glycosaminoglycans and adhesive pro-
teins is hypothesized to support the morphological, physiological
and biochemical properties of bioengineered cardiac tissues to
be more akin to native myocardium [17, 18].
Rapid preclinical progress with omental-cardiac support has
not previously been collated; therefore, we conducted a system-
atic scoping review [19]. The primary aim was to determine what
is currently known about the effectiveness of the omentum as a
biomaterial in regenerative strategies for in vivo models of myo-
cardial infarction (MI). The outcomes of interest that will be
explored include: (i) engraftment of bioengineered cardiac tis-
sues, (ii) tissue vascularization, (iii) reduction in pathological car-
diac remodelling and (iv) functional cardiac and haemodynamic
improvement. Gaps in the literature will be identified, and future
research directions indicated.
MATERIALS AND METHODS
Eligibility criteria for initial database search
Any English-language study in a peer-reviewed journal reporting
on the use of the omentum in bioengineered cardiac tissue was
considered in the original database search. Only original scientific
articles were included. Conference abstracts, letters, case reports,
editorials without a full text and reviews were excluded.
Search strategy and screening process
The databases Embase, Medline, PubMed, Scopus and Web of
Science were searched by 1 reviewer (H.W.) from inception until
6 August 2019. The search terms used were: (omentum OR
oment*) AND (cardiac OR heart).
Identified studies were imported into bibliographic manage-
ment software, Endnote X9 (Clarivate Analytics, Philadelphia,
PA, USA), and duplicated studies were deleted. One reviewer
(H.W.) screened the title and abstract of each citation. For each
eligible citation, the full text was obtained and independently
screened by 2 reviewers (H.W. and C.D.R.) for the assessment of
full-text inclusion. Reference lists of included articles were also
searched for additional studies not captured by the original
search. Disagreements were resolved by discussion. The criteria
for full-text inclusion were as follows:
• The use of the greater omentum as a biomaterial, flap or in
omentopexy;
• An ischaemic cardiomyopathy model (animal and/or
human tissue);
• The implantation of biomaterials, including non-cardiac cell
types, onto the infarcted heart; and
• Implantation efficacy expressed in terms of morphological,
biochemical or physiological integration with host tissue.
Data extraction
Extraction tables were used to standardize the collection of data from
the included studies (Tables 1–6). One reviewer (H.W.) extracted the
data initially, and the second reviewer verified the data (C.D.R.).
RESULTS
Study selection and characteristics of studies
The process of study selection into the review is represented in
Fig. 1, a PRISMA flowchart [37]. A total of 17 studies met the in-
clusion criteria. The 11 comparable studies using a pedicled
omental flap technique underwent comparable data extraction
(Tables 1–4). Those using non-comparable methodologies [31–
33] or control groups [34–36] were separated out and are dis-
played in Tables 5 and 6, respectively.
Of the 17 selected studies, 6 used a rat MI model [23, 25, 29, 30,
33, 35], 7 used a porcine MI model [20–22, 24, 28, 32, 34], 3 used a
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Bioengineering cardiac tissue involved a variety of approaches,
including the use of skeletal myoblast cells [20, 24, 25, 31, 34],
cells derived from the omentum itself [31, 32], scaffolds for factor
delivery [26–28, 33], atrial tissue [29], hepatic tissue [35], uterine
tissue [36] and stem cells [21–23, 30].
Fourteen studies transplanted the bioengineered tissue onto
the MI and/or peri-infarct area whereas the remaining 3 [21, 31,
32] reported the injection of cells into the same areas.
Effects of omentum support on bioengineered
tissue engraftment
Measures of engraftment were reported in 9 methodologically
comparable studies (those using a pedicled omental flap to sup-
port bioengineered tissue) using various metrics at various time
points (Table 2). They were tested between the time period of
7 days to 3 months across these studies, with most reporting
effects in 4 weeks or less after treatment.
Transplanted cell retention. In 6 methodologically compar-
able studies, cell survival was evaluated following transplantation
(Table 2) [22, 23, 25, 29, 30, 34]. Only one study [23] found that the
omentum had no effects in promoting cell survival. All remaining
studies reported greater cell survival and/or decreased apoptosis
for omentum-supported treatment compared to bioengineered tis-
sue applied without supportive omentopexy (Table 2).
Cell markers. From all of the 17 selected studies, the most
common report of a structural integration marker was the presence
of connexin-43, a gap junction protein, critical for propagation of
the depolarization impulse between transplanted cells and host
myocardium [30, 32, 33, 36]. In 2 of these studies, a higher expres-
sion of connexin-43 was observed in omentum-supported groups
compared to treatment without omentum [30, 32]. Only one paper
reported on the presence of troponin-T and actinin staining to cor-
roborate microscopic observations of distinctive bundled cardiac
muscle structures in transplanted tissue [33]. However, this was not
compared to their frequency in control groups.
Structural integration. Two of 17 studies described fibre or-
ganization of the bioengineered tissue [22, 33]. Omentum-
supported neonatal cardiac cells in an alginate scaffold and cardi-
omyocyte cell sheets transplanted onto ischaemic myocardium
both exhibited desirable attributes, such as striation and elongation
[22, 33]. Kawamura et al. [22] reported that the omentum contrib-
uted to the further maturation of induced pluripotent stem cell-
derived cardiomyocytes, characterized by larger cells with well-
aligned and organized sarcomere structures with positive staining
for myosin heavy chain and myosin light chain-2 in the trans-
planted area at 2 months after omentum-supported treatment.
Infarct size. In the 4 methodologically comparable studies
examining changes in infarct size, 2 reported a decrease after
Table 1: Studies which used a pedicled omental flap as support for bioengineered tissue to regenerate the myocardium








Bioengineered cardiac tissue Mode of tissue delivery
Kainuma et al. [20] 2015 Pig LCA 2 weeks 11 Skeletal myoblast cell sheet Transplantation onto MI/
peri-infarct area












area. Attached using fibrin
glue




Suzuki et al. [25] 2009 Rat LAD At initial procedure 10 Myocardial cell sheets Transplantation onto MI
area














Zhang et al. [29] 2011 Rat LCA 3 weeks 17 Autologous tissue patch
from left atrial appendage
Transplantation onto MI
area






aDefined as the treatment group in which both the bioengineered cardiac tissue and greater omentum were applied.
bFGF: basic fibroblast growth factor; Cx: circumflex coronary artery; D1: first diagonal artery; iPSC: induced pluripotent stem cell; LAD: left anterior descending
coronary artery; LCA: left coronary artery; MI: myocardial infarction; OM1 + 2: obtuse marginal coronary artery 1 and 2.
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omentum-supported treatment compared to the control group not
using the omentum [24, 27] and 2 reported no difference [23, 29].
Omentum support was shown to increase myocardial wall thickness
in 2 methodologically comparable studies [20, 26] and one that did
not use a pedicled omental flap [33], although 2 studies showed no
significant difference with omental flap support [27, 29]. All studies
that examined percentage collagen in the myocardium demon-
strated collagen attenuation, leading to decreased cardiac fibrosis,
in omentum-supported treatment [20, 30, 35].
Overall results showed that omentum support had a favour-
able effect on the engraftment of cells for bioengineering strat-
egies to regenerate the heart after MI.
Effects of omentum support on vascularization
Blood vessel formation. Direct blood vessel communication
between the bioengineered tissue and omentum was observed in
4 methodologically comparable studies as contributing to a net-
work of vessels that would anastomose with the host myocar-
dium (Table 3 and Fig. 2) [20, 21, 26, 27]. Whilst most
comparable studies demonstrated that support with a pedicled
omental flap led to greater vessel density in the transplantation
area, there were variable reports of whether arteriolar or capillary
density was increased (Table 3).
Of all 17 selected studies, 7 reported that arteriolar density was
improved [21, 23, 25–28, 35], whilst 5 reported that capillary
density had improved [22, 25, 30, 31, 35] and 2 did not specify
vessel diameter [20, 33]. No negative relationship between blood
vessel density and use of omentum support was reported in any
study.
Angiogenic markers. Of all 17 selected studies, many corro-
borated the observation of increased vascularization with the up-
regulated expression of genes related to angiogenesis [20, 22, 24,
25, 28–30, 33, 35]. The most commonly reported up-regulated
gene in omentum-supported tissue was vascular endothelial
growth factor [20, 22, 24, 25, 30, 35]. There were also reports of
increased basic fibroblast growth factor [22, 35] and smooth
muscle actin [28, 33].
Blood flow. Taken together, these results suggested that
omentum support conveyed a proangiogenic effect. However,
despite the potential for this to lead to increased myocardial
blood flow or coronary flow reserve, only 2 studies in total
reported that treatment supported by the omentum was superior
to that of other treatment groups for blood flow [20, 26]. Two
studies reported that omentum support made no significant dif-
ference to observed blood flow [21, 28].
Effects of omentum-supported bioengineered tis-
sue on cardiac remodelling and function
Remodelling. Eight studies reported that bioengineered tissue
supported with a pedicled omental flap decreased cardiac
remodelling (Table 4). Seven studies reported a decrease in left
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Table 2: Measures of engraftment outcomes of bioengineered cardiac tissue with omentum




























Kainuma et al. [20] Engrafted area remaining with time Collagen content
Day 7 = 0.3 mm2 Day 7 = 0.07 mm2 8% 13%
Day 28 = 0.15 mm2 Day 28 = 0.05 mm2 LV wall thickness
912 mm 688 mm
Myocyte size
16 mm 20 mm
Key findings 3–4 increased area of grafted cells
remained in situ with omentum supporta
Scar collagen attenuation, less thick LV wall,




Cell % survival rate Myosin heavy chain/myosin light chain-2
positive (striated filaments)
1 month = 90%
3 months = 58%
1 month = 61%
3 months = 24%
Present Not reported
Key findings Improved grafted cell survival with
omentum supporta
Well-organized sarcomere structure
in cells with omentum
support (not compared to
control)
Lilyanna et al. [23] Bioluminescence photon emission flux
of labelled live donor cells (photons/s)
Scar size (LV cross sectional area
% containing fibrosis)
Day 1 = 6.5 107
Day 14 = 1.5 105
Day 1 = 7.6 107
Day 14 = 6.8 105
34.7% 35.7%
Key findings Donor cell attrition rate in vivo over
time comparable with or without
omentum support
Minimal difference in scar with or
without omentum support
Shudo et al. [24] Infarct area
6% 11%
Key findings Infarct size (infarcted LV/total LV estimated
by computer-based planimetry of
Masson trichrome-staining) reduced with
omentum supporta
Suzuki et al. [25] Cardiomyocyte survival
46% 31%
Cell sheet thickness
120 lm 70 lm
Key findings Improved graft survival with omentum
support
Takaba et al. [26] Dynamic % wall thickening of infarct region
49% 41%
Key findings % fractional wall thickening (assessed by
cine MRI for quantitative wall motion)
increased with omentum support
Ueyama et al. [27] Infarct size
10% 16%
LV circumference
48 mm 56 mm
Scar circumference
16 mm 24 mm
Infarct area wall thickness
2.5 mm (ns) 2.0 mm (ns)
Key findings Reduced infarct size, dilatation and scar. No
significant difference in wall thickness
Zhang et al. [29] Atrial tissue patch graft presence
after 4 weeks
Scar thickness
In situ Not seen 0.4 mm (ns) 0.35 mm (ns)
Infarct size
38% (ns) 39% (ns)
Continued
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ventricular end-diastolic diameter in the range of 2–25%, and 5
studies reported a decrease in left ventricular end-systolic diam-
eter in the range of 10–27% (Table 4). For reverse remodelling,
the study that reported the most beneficial effect did not involve
a pedicled omental flap, but rather pre-vascularization of a car-
diac patch on the omentum, supplemented with angiogenic fac-
tors, before transplanting the patch without omentopexy onto
the heart [33]. Nevertheless, combining bioengineered tissue with
an omental flap favoured reverse remodelling, especially at 4
weeks or later after intervention (Table 4).
Function. The most common measure of functional improve-
ment reported was the left ventricular ejection fraction (LVEF).
Omentum-supported bioengineered tissue improved the LVEF by
up to 82% as a relative increase on absolute values compared to
controls receiving bioengineered tissue alone (Table 4). Conversely,
omentopexy alone without a bioengineered tissue was not enough
to significantly improve LVEF [25, 29]. Results for fractional shorten-
ing and fractional area change were reported with less frequency
than LVEF with only 3 studies reporting a significant increase in
fractional shortening [26, 29, 30] and 1 study reporting an increase
in fractional area change [27] with omentum support (Table 4).
DISCUSSION
This is the first review that systematically evaluates the effects of
omentum support for bioengineering of cardiac tissues in MI mod-
els in vivo. Although all the included studies demonstrated that the
omentum conferred a benefit in at least one of the outcomes
assessed (engraftment, vascularization, remodelling, function), only
a few studies reported on all outcomes. Furthermore, a few did not
contain optimal control groups. This makes it difficult to draw con-
clusions of how effective the omentum is compared to controls or
other bioengineering strategies. Our results highlight the variability
of methodologies and results between studies (such as the treat-
ment modality combined with the omentum, the model of MI and
the outcome measures). This limits the extent to which the benefit
of the omentum can be compared across studies.
The synergistic proangiogenic potential of omentum-
supported bioengineered tissue was instrumental in most studies
to promoting greater vascularization than bioengineered treat-
ment or omentopexy alone. The development of a microvascula-
ture between the coronary and gastroepiploic circulation was
reported (Fig. 2) [20, 21, 26, 28]. The up-regulation of several
angiogenic genes and proteins (e.g. vascular endothelial growth
factor and smooth muscle actin) suggested that angiogenesis and
vessel maturation are supported by the omentum (Table 3).
However, most studies demonstrated that enhanced vasculariza-
tion of the bioengineered tissue did not ultimately correlate with
increased myocardial blood flow [20, 21, 28, 34]. Therefore, add-
itional studies are needed to make progress from these results
before they can be translated into clinical trials.
As shown in Table 4, bioengineered tissues with omentum
support reported positive effects on cardiac function at 4 weeks
in 6 studies. Suzuki et al. [25] reported an improvement at 1
week, and Kawamura et al. [22] reported an improvement at 3
months. All studies reporting a significant positive effect on func-
tion (Table 4) also reported enhanced vascularization (Table 3).
Five studies reported both improved engraftment and cardiac
function (Tables 2 and 4). Altogether, this suggests that both vas-
cularization and engraftment are required for a cardiac functional
improvement. Furthermore, 2 studies [25, 29] showed that the
omentum by itself did not significantly improve cardiac function.
Despite promising functional results, future studies would benefit
from observations of long-term outcomes as some measure-
ments, such as LVEF, have limited prognostic power in predicting
clinical benefit across long time horizons.
Table 2: Continued




























Key findings Troponin-stained graft survived
with omentum support but did not
without omentum support
No significant difference in scar thickness
or infarct size with or without
omentum supporta
Zhou et al. [30] Quantification PCR of grafted cellsb Connective protein Cx-43 expressionc Collagen (scar) density
Week 1 = 14.1 units
Week 4 = 2.6 units
Week 1 = 3.8 units
Week 4 = 1.2 units
0.23 units 0.19 units 16% 26%
Key findings Cell survival rate in vivo over time
improved with omentum support
Higher levels of Cx-43 suggested
enhanced structural coupling
of transplanted cells to host myocardium.
Sham group (baseline) level = 0.31; MI
with no treatment group level = 0.11
Reduced % fibrillar collagen in the
infarction zone (semiquantitatively meas-
ured by picrosirius red staining under
polarized light microscopy)
aNumerical data extrapolated from graphical figure.
bUnits expressed as ratio of optical density under UV light compared to reference sample at the same time.
cCx-43 protein expression determined by western blot. Units expressed as ratio to the level of b-actin which was run on all blots.
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Table 3: Measures of vascularization outcomes of bioengineered cardiac tissue with omentum















Kainuma et al. [20] Total CD31+ endothelial cells (mature and immature
vessels)








425 cells/mm2 275 cells/mm2 225 mm 170 mm
Functionally mature vessels (CD31+/Lecithin+) 2nd–4th branch vessel diameter
375 cells/mm2 225 cells/mm2 No difference No difference
Structurally mature vessels (CD31+/SMA+) Resistance vessels (3rd–4th order)
120 cells/mm2 30 cells/mm2 2–3more vessels 2–3 fewer vessels
% Maturation (structurally mature vessels/total) Acetylcholine challenge (resistance vessel diameter
dilation)
31% 12% 28% (3rd order vessels)
32% (4th order vessels)
18% (3rd order vessels)
21% (4th order vessels)
Gastroepiploic-coronary anastomoses Dobutamine challenge (resistance vessel diameter
constriction)
Present (Absent)b 31% (3rd order vessels)
34% (4th order vessels)
9% (3rd order vessels)
29% (4th order vessels)
Gastroepiploic-coronary anastomotic tight junctions Global CFR change (ratio pre:post-treatment)
Present (Absent)b 1.3 0.9
Gastroepiploic-coronary anastomotic ink leakage MBF (resting or stressed)
Minimal (Widespread)b No difference No difference
Key findings 1. Increase in total vascularity and mature vascular-
ity peri-infarct at 28 days with omentum supporta
2. Anastomoses formed between omental and cor-
onary circulation only if bioengineered tissue
omentum-supported
1. Greater number and responsiveness of resistance
vessels (3rd–4th order in descending hierarchy of
calibre)
2. Increase in global CFR change and no change in








Kanamori et al. [21] Arteriole (>50 mm) density Regional MBF (infarct or non-infarct wall, resting or
stressed)
27/mm2 18/mm2 No difference No difference
Capillaries (<50 mm) density Regional MBF ratio infarct: non-infarct wall (resting
or stressed)
109/mm2 (ns) 88/mm2 (ns) No difference No difference
Gastroepiploic-coronary anastomoses via omentum-
supported tissue
Present No comparison data
Key findings 1. Arteriole density increased but no significant dif-
ference for capillaries (<50 mm)
2. Anastomoses formed between omental and cor-
onary circulation via omentum-supported bioen-
gineered tissue
No difference in regional MBF (assessed by spectro-
photometry of coloured microsphere cardiac injec-
tion with femoral arterial blood reference sampling)
with omentum support compared to bioengineered
tissue without omentum support
Kawamura et al. [22] Capillary density VEGF (endothelial cells)
bFGF (fibroblasts/
angiogenesis)
111 units/mm2 51 units/mm2
Key findings Increased capillary density at the transplanted area
(assessed by semiquantitative immunohistochemistry






Lilyanna et al. [23] Functional blood vessels as % of LV scar area
18% 8%
Structural blood vessels
6/hpf (400) 3/hpf (400)
Key findings Increased vascularity with functional staining (infused
DiI+ vesselsc) and structural staining (Masson’s tri-
chrome) with omentum support
Shudo et al. [24] Capillary density VEGF (endothelial cells)
vWF (endothelial cells)170/mm2 125/mm2
Key findings Increased capillaries (anti-vWF antibody immunola-
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Table 3: Continued















Suzuki et al. [25] Small vessels VEGF (endothelial cells)
vWF (endothelial cells)70/hpf 20/hpf
Key findings Increased small vessels observed (anti-vWF antibody





Takaba et al. [26] Arteriole (>50 mm) density Regional MBF
31 vessels/mm2 26 vessels/mm2 2.8 ml/min/g 2.3 ml/min/g
Gastroepiploic-coronary anastomoses via omentum-
supported tissue
Regional MBF drop on clamping gastroepiploic artery
pedicle
Present No comparison data 2.8–1.9 ml/min/g No comparison data
Key findings 1. Increased arterioles (anti-SMA antibody immuno-
labelled arterioles) with omentum support
2. Anastomoses formed between omental and cor-
onary circulation via omentum-supported bioen-
gineered tissue
1. Infarct regional MBF increased with omentum
support
2. Clamping gastroepiploic pedicle for omentum-
supported bioengineered tissue caused 32% drop
in host infarct regional MBF
Ueyama et al. [27] Arteriole (20–100 lm) density Subjects with LV collateral vessels on angiography via
gastroepiploic artery pedicle
23/mm2 14/mm2 7/7 (2/7)b
Collateral vessel description
Rich (Poor)b
Patent collateral vessel proportion (angiographic
score)
0.8 (0.1)b
Key findings Increased arterioles (anti-SMA antibody immunola-
belled arterioles) with omentum support
Dye injection into gastroepiploic pedicle at immedi-
ate post-mortem angiography showed favourable
collateral vessel patency for omentum-supported














31/mm2 20/mm2 1.3 (ns) 1.0 (ns)
Capillary (CD31+) density Territorial and regional MBF
98/mm2 (ns) 90/mm2 (ns) No difference No difference
Vessels >100 mm diameter CFR proportional change on occlusion of Cx artery
with gastroepiploic pedicle not occluded
1.5/mm2 (ns) 1.2/mm2 (ns) 1.0 (0.7)b
Key findings Increased arteriole (CD31+ and SMA+ vessels) density
and no difference for capillaries (CD31+ vessels) or
>100 mm diameter vessels in peri-infarct area with
omentum supporta
1. No significant difference in MBF with omentum
support
2. On clamping the Cx coronary artery for subject
animals with LAD infarcts there was no change in
CFR with omentum-supported bioengineered tis-
sue compared to a 30% drop in CFR with omento-





Zhang et al. [29] Capillary (VEGF+) density VEGF (endothelial cells)
(ns)48/0.2 mm2 (ns) 28/0.2 mm2 (ns)
Key findings No difference in capillary (VEGF+ vessels) density
with omentum support versus bioengineered tissue
alonea
No difference in up-
regulation of VEGF
Zhou et al. [30] Microvessel (vWF+) density VEGF (endothelial cells)
226/mm2 109/mm2
Key findings Increased vessel (anti-vWF antibody immunolabelled




aNumerical data extrapolated from graphical figure.
bComparison to bioengineered tissue without omentum support is not applicable for this assay as no connection to gastroepiploic circulation is possible in this
group. Therefore control group result is for omentopexy alone (no bioengineered tissue).
cDiI is DiIC18 (1,10-dioctadecyl-3,3,30 ,30-tetramethylindocarbocyanine perchlorate) fluorescent dye.
Ang-1: angiopoietin 1; bFGF: basic fibroblast growth factor; CFR: coronary flow reserve; Cx: circumflex coronary artery; LV: left ventricle; MBF: myocardial blood
flow; ns: result not statistically significant; PDGF-b: platelet-derived growth factor-b; PECAM: platelet endothelial cell adhesion molecule; SMA: smooth muscle
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Limitations
Limitations of this review include those inherent to the scoping
review methodology, namely that other relevant studies may not
have been included. Aside from those not in English, there re-
main innovative in vitro studies utilizing the omentum for bioen-
gineered cardiac tissue that fell outside the scope of this review
because they were not tested in vivo. Most studies captured by
our scoping review used a pedicled omental flap, which is feas-
ible in human surgery. This is perhaps why it featured so promin-
ently and may lend itself to a smooth translation from the
laboratory into clinical practice. However, only 17 publications
out of 1926 were admissible for the lack of translation of in vitro
work into in vivo experiments, which highlights a gap between
scientists and clinicians. This should be addressed in all future
studies to facilitate translating preclinical in vivo studies to human
trials.
The tendency towards positive results from the studies found
in this review may also present a publication bias. No studies in
this review reported a detrimental effect and only a few reported
no overall difference as a result of omentum support. This was
despite the cardiac and diaphragmatic impairment that an
omentopexy might cause in animal models. The results may also
present attrition bias whereby animals that died as the result of
the initial grafting procedure were not analysed. Furthermore, pre-
clinical studies that pioneer new techniques are susceptible to sci-
entific design weaknesses such as operator skill variability,
tweaking of methods during experiments, non-randomization of
animal subjects, small sample sizes and non-blinding of research-
ers [38]. Future in vivo experiments should explicitly address all of
these points, adhering to an established experimental planning
guideline, uploading protocols to un-editable repositories before
work begins and including more systematic reporting on cardiac
and respiratory functional outcomes beyond the LVEF.
Table 4: Cardiac functional outcomes of bioengineered tissue with omentum support compared to bioengineered tissue without
omentum supporta
First author LVEDD % decrease LVESD % decrease LVEF % increase FS % increase FAC % increase Measurement interval
after treatment
Kainuma et al. [20] 10% (ns)b 13% (ns)b 12% (ns)b 2 weeks
16%b 16%b 24%b 4 weeks
Kawamura et al. [22] 5% (ns) 1 month
8% (ns) 2 months
25% 26% 16% 3 months
Lilyanna et al. [23] 15% (ns) 15% (ns) 6% (ns) 4 weeks
Shudo et al. [24] 24% (ns)b 36%b 26%b 4 weeks
25% (ns)b 27%b 22%b 8 weeks
Suzuki et al. [25] 0% (ns)b 3%b 1 week
10% (ns)b 8%b 4 weeks
12%b 18%b 8 weeks
Takaba et al. [26] -3% (ns)b 82% 5% (ns)b 4 weeks
2% 36% 8 weeks
Ueyama et al. [27] 26%b 26%b 2 weeks
21% 41% 4 weeks
Yajima et al. [28] 5% (ns) 14% (ns) 34% (ns) 4 weeks
Zhang et al. [29] 8% 10% 10% 6.3% 4 weeks
Zhou et al. [30] 13% 12% 13% 11% 4 weeks
aData expressed as % decrease or % increase (whichever is the desirable outcome) between the absolute values for the omentum-supported and non-omentum-
supported groups.
bNumerical data extrapolated from graphical figure.
FAC: fractional area change; FS: fractional shortening; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LVESD: left ventricular
end-systolic diameter; ns: result not stastically significant.
Figure 2: Collateral blood vessel formation between the Cx and the GEA in omentum-supported bioengineered tissue applied to the heart in a rabbit model of Cx in-
farction. (A) The whole specimen (scale bar = 10 mm). (B) Collateral formation between occluded Cx and GEA (scale bar = 1 mm). (C) Scanning electron micrograph of
collaterals between occluded Cx and GEA. Reproduced with permission from [36]. Cx: circumflex coronary artery; GEA: gastroepiploic artery.
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The omentum has also been used in non-cardiac tissues for the
promotion of regeneration and superior bioengineering techni-
ques. In particular, the pedicled omental flap has been used in vivo
for spinal wound repair [39] and synthetic patch reconstruction of
the anterior abdominal wall [40]. Hepatocytes on biodegradable
scaffolds [41] and tracheal [42] tissue have also been shown to
grow successfully on the omentum. The common mechanism be-
hind the regenerative potential of the omentum is likely due to its
numerous paracrine factors and immunological mediators pro-
moting the optimal stem cell niche [43]. A deeper understanding
of the mechanisms regulating non-cardiac tissue regeneration may
lead to future innovative approaches in cardiac bioengineering.
CONCLUSION
The omentum is a promising tissue for cardiac bioengineering.
It has demonstrated its ability to enhance transplanted cell en-
graftment, vascularization and host cardiac function. The mech-
anisms that confer functional cardiac benefit are not fully
understood and require further experimental consideration.
Future studies that examine these mechanisms and outcomes
would benefit from a more homogenous approach to method-
ology that promotes a more detailed understanding of mechan-
istic processes and outcomes, which is important for clinical
translation.
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